Spots Global Cancer Trial Database for orelabrutinib
Every month we try and update this database with for orelabrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT06378138 | Hematologic Mal... | ICP-248 Orelabrutinib | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | NCT05021770 | Refractory and ... PCNSL Non Hodgkin Lym... | Orelabrutinib Orelabrutinib Thiotepa | 18 Years - | Sun Yat-sen University | |
| Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | NCT05334238 | Primary Central... | Orelabrutinib | 18 Years - 65 Years | Ruijin Hospital | |
| Genotype-guided Treatment in DLBCL | NCT05351346 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Orelabrutinib Lenalidomide Decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma | NCT04961515 | Primary Central... | Orelabrutinib Orelabrutinib Sintilimab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT06378138 | Hematologic Mal... | ICP-248 Orelabrutinib | 18 Years - 80 Years | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors | NCT05495828 | B-cell Lymphoma | Orelabrutinib | 18 Years - | Peking University People's Hospital | |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | NCT05390749 | Primary Central... | Orelabrutinib Pomalidomide Rituximab Methotrexate | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma | NCT05381506 | DLBCL | Orelabrutinib a... | 18 Years - | Sun Yat-sen University | |
| Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | NCT05498259 | Diffuse Large B... | Orelabrutinib Rituximab CHOP-like Regim... | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL | NCT05036577 | Primary Central... | Orelabrutinib Rituximab Methotrexate (M... Dexamethasone | 18 Years - 75 Years | Huashan Hospital | |
| A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL | NCT06363994 | Mantle Cell Lym... | Orelabrutinib Bendamustine In... Rituximab Orelabrutinib P... | 60 Years - | InnoCare Pharma Inc. | |
| Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement | NCT05926427 | CNS Lymphoma | Orelabrutinib Rituximab Chemotherapy | 14 Years - 80 Years | Ruijin Hospital | |
| A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | NCT04304040 | B-cell Lymphoma... B-cell Lymphoma... | Orelabrutinib Recombinant hum... | 18 Years - | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL | NCT05498259 | Diffuse Large B... | Orelabrutinib Rituximab CHOP-like Regim... | 18 Years - 70 Years | The First Affiliated Hospital of Soochow University | |
| Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | NCT04899427 | Primary Central... | orelabrutinib Sintilimab Tislelizumab | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma | NCT05381506 | DLBCL | Orelabrutinib a... | 18 Years - | Sun Yat-sen University | |
| A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma | NCT04304040 | B-cell Lymphoma... B-cell Lymphoma... | Orelabrutinib Recombinant hum... | 18 Years - | Beijing InnoCare Pharma Tech Co., Ltd. | |
| Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | NCT05809180 | Diffuse Large B... | Rituximab Orelabrutinib Pomalidomide Pro-miniCHOP-li... R-miniCHOP-like... | 70 Years - | The First Affiliated Hospital of Soochow University | |
| Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | NCT05390749 | Primary Central... | Orelabrutinib Pomalidomide Rituximab Methotrexate | 18 Years - 70 Years | Peking Union Medical College Hospital | |
| Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients | NCT05809180 | Diffuse Large B... | Rituximab Orelabrutinib Pomalidomide Pro-miniCHOP-li... R-miniCHOP-like... | 70 Years - | The First Affiliated Hospital of Soochow University | |
| Genotype-guided Treatment in DLBCL | NCT05351346 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Orelabrutinib Lenalidomide Decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| Genotype-guided Treatment in DLBCL | NCT05351346 | Diffuse Large B... | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Orelabrutinib Lenalidomide Decitabine | 18 Years - 80 Years | Ruijin Hospital | |
| An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL | NCT06015464 | Lymphoma, Large... | Orelabrutinib | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | NCT05334238 | Primary Central... | Orelabrutinib | 18 Years - 65 Years | Ruijin Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
